Low-dose temozolomide selectively increases glioblastoma’s vascular permeability, tumor microenvironment penetration and the killing potential of systemic actinium-225 α-particle dendrimer-radioconjugates improving treatment efficacy
European Journal of Nuclear Medicine and Molecular Imaging · 2025
DOI: 10.1007/s00259-025-07332-w ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2025. Verfasst von Rajiv Ranjit Nair und 11 weiteren Autor:innen. Beteiligte Einrichtung: Chemical and Biomolecular Engineering (ChemBE), Institute for NanoBioTechnology (INBT), Johns Hopkins University, Baltimore, MD, USA. Hauptthemen laut MEDLINE: Glioblastoma, Dendrimers, Actinium, Alpha Particles. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Hartwell Foundation, Uncle Kory Foundation.
Abstract (Originalsprache)
PURPOSE: The poor prognosis of glioblastoma is mostly due to the relatively low tumor vascular permeability to therapeutics, the tumor's vicinity to the brain, that limits treatment aggressiveness, and/or drug resistance. METHODS: In this study, the efficacy of systemically injected actinium-225 dendrimer-radioconjugates was evaluated in an immune-competent orthotopic GL261-C57BL/6 mouse model after administration of low-dose, standard-of-care temozolomide, that selectively increased the tumor vascular permeability to dendrimer-radioconjugates. Alpha-particles' short range in tissue combined with the dendrimers' selective uptake by glioblastomas, could limit the irradiation of the neighboring brain, while the complex double-strand DNA breaks caused by α-particles were expected to be largely impervious to resistance by cancer cells. RESULTS: On mice bearing 9.7 ± 5.7mm3 brain tumors, at activities that did not cause long-term (11-months) toxicities, dendrimer-radioconjugates, that were systemically-administered 24-hours after injection of temozolomide, significantly improved survival compared to dendrimer-radioconjugates alone (44 vs. 39 days mean survival, p = 0.0017) and/or compared to temozolomide alone and/or to non-treated animals (31 and 30 days, p < 0.001). This was attributed to: (1) the noteworthy increase (by 33%) in tumor absorbed doses delivered by dendrimer-radioconjugates when injected after chemotherapy, without altering normal organ (including the brain's) dosimetry; (2) the potentially deeper tumor penetration of dendrimer-radioconjugates, suggested by the enhanced dendrimer penetration within GL261-spheroids, employed as model tumor-avascular regions; and/or (3) the formation of a more lethal cocktail when both modalities acted on same cancer cells. CONCLUSIONS: This study demonstrates the potential and safety of actinium-225 dendrimer-radioconjugates as a systemic α-particle radiotherapy for glioblastoma enhanced by low-dose temozolomide.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Chemical and Biomolecular Engineering (ChemBE), Institute for NanoBioTechnology (INBT), Johns Hopkins University, Baltimore, MD, USA.
- Molecular and Comparative Pathobiology, Johns Hopkins University, Baltimore, MD, USA.
- Center for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD, USA.
- Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, MD, USA.
- Chemical and Biomolecular Engineering (ChemBE), Institute for NanoBioTechnology (INBT), Johns Hopkins University, Baltimore, MD, USA. ssofou1@jhu.edu.
- Sidney Kimmel Comprehensive Cancer Center, Cancer Invasion & Metastasis Program, Department of Oncology, Johns Hopkins University, Baltimore, MD, USA. ssofou1@jhu.edu.
ORCID-Profile: Stavroula Sofou
Förderung
- Hartwell Foundation
- Uncle Kory Foundation
Zitieren
APA
Nair, R. R., Sarkar, A., Hariharan, P., Gabrielson, K. L., Wu, T., Liu, C., Sharma, A., Liyanage, W., Bhujwalla, Z. M., Vidaver, M. P., Kannan, R. M., & Sofou, S. (2025). Low-dose temozolomide selectively increases glioblastoma’s vascular permeability, tumor microenvironment penetration and the killing potential of systemic actinium-225 α-particle dendrimer-radioconjugates improving treatment efficacy. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07332-w
Vancouver
Nair RR, Sarkar A, Hariharan P, Gabrielson KL, Wu T, Liu C, et al. Low-dose temozolomide selectively increases glioblastoma’s vascular permeability, tumor microenvironment penetration and the killing potential of systemic actinium-225 α-particle dendrimer-radioconjugates improving treatment efficacy. European Journal of Nuclear Medicine and Molecular Imaging. 2025. doi:10.1007/s00259-025-07332-w
BibTeX
@article{Nair2025,
author = {Nair, Rajiv Ranjit and Sarkar, Aira and Hariharan, Pooja and Gabrielson, Kathleen L and Wu, Tony and Liu, Chang and Sharma, Anjali and Liyanage, Wathsala and Bhujwalla, Zaver M and Vidaver, Marie-France Penet and Kannan, Rangaramanujam M and Sofou, Stavroula},
title = {Low-dose temozolomide selectively increases glioblastoma’s vascular permeability, tumor microenvironment penetration and the killing potential of systemic actinium-225 α-particle dendrimer-radioconjugates improving treatment efficacy},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2025},
doi = {10.1007/s00259-025-07332-w}
}
EUVIMED